Feature Channels:

Pharmaceuticals

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Research, Depression, O’Donnell Jr. Brain Institute , Peter O’Donnell Jr. Brain Institute, Ut Southwestern

Study Answers Why Ketamine Helps Depression, Offers Target for Safer Therapy

monteggia-lisa-body.jpg

UT Southwestern Medical Center scientists have identified a key protein that helps trigger ketamine’s rapid antidepressant effects in the brain, a crucial step to developing alternative treatments to the controversial drug being dispensed in a growing number of clinics across the country.

Medicine

Channels:

UTHealth

UTHealth’s Lenard Lichtenberger Tests Effectiveness of Lipidic Aspirin Formulation Against Cancer

LenardLichtenberger.jpg

Scientists at The University of Texas Health Science Center at Houston (UTHealth) are testing the effectiveness of a soy-enriched aspirin formulation designed to fight colorectal cancer with fewer side effects.

Medicine

Channels:

AML, Leukemia, gilteritinib, FLT3

New Inhibitor Drug Shows Promise in Relapsed Leukemia

Perl.Alexander_WhiteCoat.jpg

A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers at the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center. The Fms-like tyrosine kinase 3 (FLT3) gene mutation is a known predictor of AML relapse and is associated with short survival. In a first-in-human study, researchers treated relapsed patients with gilteritinib, an FLT3 inhibitor, and found it was a well-tolerated drug that led to frequent and more-sustained-than-expected clinical responses, almost exclusively in patients with this mutation.

Medicine

Channels:

Finding the Perfect Match: A New Approach to Battle Drug-Resistant Bacteria

Antibiotics were the wonder drug of the 20th century, but bacteria evolved resistance. According to the CDC, more than 2 million people in the U.S. develop MDR infections every year. Researchers at Univ. of Utah developed a rapid screen to pair existing FDA-approved drugs to combat MDR infections.

Business

Channels:

UNC/N.C. State Spinout Company Raises $5.8M for ‘Smart’ Insulin Devices

Technology invented in a laboratory in the UNC-NC State Joint Biomedical Engineering Program could soon mean painless diabetes testing and insulin injections for the nearly 400 million people with diabetes worldwide.

Medicine

Channels:

ASHP, choosing wisely campaign, Medication Safety, ABIM Foundation, Consumer Reports, Pharmacy, paul abramowitz, Choosing Wisely , Advocacy, medication use, Patient Safety

ASHP Contributes Medication-Use Recommendations to Choosing Wisely Campaign

ASHP (American Society of Health-System Pharmacists) released five recommendations to facilitate optimal medication use for patients in acute and ambulatory care settings as part of the Choosing Wisely® campaign.

Medicine

Channels:

Opioids, Chronic Pain, Studies, American Society Of Anesthesiologists

Women Who Focus Negatively, Magnify Chronic Pain, More Likely to Be Taking Prescribed Opioids

Female chronic pain sufferers who catastrophize, a psychological condition in which pain is exaggerated or irrationally focused on, not only report greater pain intensity, but are more likely to be taking prescribed opioids than men with the same condition, according to a study published Online First in Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists (ASA).

Medicine

Channels:

Thyroid Cancer, radioiodine therapy, radioiodine-refractory thyroid cancer, Levatinib

Inhibitor Drug Improves Overall Survival in Older Radioiodine Resistant Thyroid Cancer Patients

brose_marcia.JPG

The drug lenvatinib can significantly improve overall survival rates in a group of thyroid cancer patients whose disease is resistant to standard radioiodine treatment, according to new research from the Perelman School of Medicine at the University of Pennsylvania. The study, published today in the Journal of Clinical Oncology, is the first to show lenvatinib has a definitive impact on overall survival (OS). Researchers found OS improves in patients older than 65 years of age and that the drug is well-tolerated.

Medicine

Channels:

Muscle, Muscle Regeneration, Regeneration

SLU Researchers Find Key to Muscle Regeneration

BurrisandFlaveny.jpg

The nuclear receptor REV-ERB plays a key role in muscle regeneration, suggesting the receptor may be a good target for new drugs to treat a variety of muscle disorders and injuries.

Medicine

Channels:

Experimental Drug Co-Developed by Moffitt Cancer Center Researcher Shows Promise

The investigation found that the drug, geranylgeranyltransferase inhibitor GGTI-2418 suppresses a new defective PTEN cancer pathway discovered by Pagano’s group.







Chat now!